Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, S.E.[Yoon, S.E.] | - |
dc.contributor.author | Jo, H.[Jo, H.] | - |
dc.contributor.author | Kang, E.-S.[Kang, E.-S.] | - |
dc.contributor.author | Cho, D.[Cho, D.] | - |
dc.contributor.author | Cho, J.[Cho, J.] | - |
dc.contributor.author | Kim, W.S.[Kim, W.S.] | - |
dc.contributor.author | Kim, S.J.[Kim, S.J.] | - |
dc.date.accessioned | 2022-05-02T00:43:34Z | - |
dc.date.available | 2022-05-02T00:43:34Z | - |
dc.date.created | 2022-05-02 | - |
dc.date.issued | 2022-04 | - |
dc.identifier.issn | 0268-3369 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/96587 | - |
dc.description.abstract | The role of upfront autologous stem cell transplantation (ASCT) remains unclear in patients with primary central nervous system lymphoma (PCNSL) receiving rituximab and high-dose methotrexate (MTX)-based chemotherapy. We analyzed the outcomes of upfront ASCT in 106 patients with PCNSL (median age, 64 years; range, 34–86) who received rituximab, MTX, vincristine, and prednisolone (R-MVP). The objective response rate was 88.7% (94/106) and included 46 complete responses (43.4%). Upfront ASCT was performed in 38 responders (median age, 51 years; range, 34–69), including 13 patients aged >60 years, after conditioning with busulfan (3.2 mg/kg, days 8 to 5) and thiotepa (5 mg/kg, days 4–3). For 56 responders ineligible for ASCT because of age >70 years, poor performance status, or refusal to undergo upfront ASCT, other consolidation treatments (n = 32) or observation (n = 24) were performed. With a median follow-up of 24.4 months (95% confidence interval, 20.7–28.0 months), no transplantation-related deaths occurred and seven patients relapsed after upfront ASCT. By contrast, 24 relapses occurred in patients who did not receive upfront ASCT. The progression-free and overall survival were significantly better in patients undergoing upfront ASCT (P = 0.001). Our real-world data suggest the benefit from upfront ASCT. © 2022, The Author(s), under exclusive licence to Springer Nature Limited. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Springer Nature | - |
dc.title | Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, S.E.[Yoon, S.E.] | - |
dc.contributor.affiliatedAuthor | Jo, H.[Jo, H.] | - |
dc.contributor.affiliatedAuthor | Kang, E.-S.[Kang, E.-S.] | - |
dc.contributor.affiliatedAuthor | Cho, D.[Cho, D.] | - |
dc.contributor.affiliatedAuthor | Cho, J.[Cho, J.] | - |
dc.contributor.affiliatedAuthor | Kim, W.S.[Kim, W.S.] | - |
dc.contributor.affiliatedAuthor | Kim, S.J.[Kim, S.J.] | - |
dc.identifier.doi | 10.1038/s41409-022-01605-w | - |
dc.identifier.scopusid | 2-s2.0-85124901426 | - |
dc.identifier.wosid | 000757536000001 | - |
dc.identifier.bibliographicCitation | Bone Marrow Transplantation, v.57, no.4, pp.641 - 648 | - |
dc.relation.isPartOf | Bone Marrow Transplantation | - |
dc.citation.title | Bone Marrow Transplantation | - |
dc.citation.volume | 57 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 641 | - |
dc.citation.endPage | 648 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biophysics | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Transplantation | - |
dc.relation.journalWebOfScienceCategory | Biophysics | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Transplantation | - |
dc.subject.keywordPlus | INTERNATIONAL EXTRANODAL LYMPHOMA | - |
dc.subject.keywordPlus | NERVOUS-SYSTEM LYMPHOMA | - |
dc.subject.keywordPlus | HIGH-DOSE CHEMOTHERAPY | - |
dc.subject.keywordPlus | WHOLE-BRAIN RADIOTHERAPY | - |
dc.subject.keywordPlus | GRAFT FAILURE | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | CHEMOIMMUNOTHERAPY | - |
dc.subject.keywordPlus | RANDOMIZATION | - |
dc.subject.keywordPlus | CONSOLIDATION | - |
dc.subject.keywordPlus | CYTARABINE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.